CWM
AUTL

Curi Wealth Management’s Autolus Therapeutics AUTL Stock Holding History

Curi Wealth Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-137
Closed – – 228
2022
Q2 		$0 Buy
+137
New +$417 ﹤0.01% 621

Other funds holding AUTL

Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
PG
Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Curi Wealth Management's AUTL Position: Q3 2022 in Review

Curi Wealth Management sold out of Autolus Therapeutics (AUTL) in Q3 2022, closing a stake of 137 shares.

Curi Wealth Management first reported a position in AUTL in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 66 funds tracked by Wall St. Rank hold AUTL as of Q3 2022.

  • Curi Wealth Management reported no remaining Autolus Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Curi Wealth Management sold 137 Autolus Therapeutics shares in Q3 2022.
  • Curi Wealth Management first reported a position in Autolus Therapeutics in Q2 2022 and held it in 1 quarter.
  • Curi Wealth Management's Autolus Therapeutics position peaked at $0 in Q2 2022.
  • 66 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2022.

Based on Curi Wealth Management's 13F filing for Q3 2022, filed 8 Nov 2022.